Polyrizon Ltd. (PLRZ) — 6-K Filings

6-K Filings (45)

• 6-K Filing — May 4, 2026
• 6-K Filing — Apr 8, 2026
• 6-K Filing — Dec 29, 2025
• Polyrizon seeks FDA designation for viral blocker — Dec 19, 2025 Risk: medium
  Polyrizon Ltd. announced on December 19, 2025, that it has submitted a pre-request for designation to the U.S. Food and Drug Administration (FDA) for its PL-16
• Polyrizon Ltd. Advances Intranasal Naloxone Hydrogel Program — Dec 11, 2025 Risk: medium
  Polyrizon Ltd. announced on December 11, 2025, promising permeation kinetics for its intranasal naloxone hydrogel program. This development supports the advance
• Polyrizon Ltd. Completes FDA Pre-Submission Meeting for Allergy Blocker — Dec 8, 2025 Risk: medium
  Polyrizon Ltd. announced on December 8, 2025, that it has completed a Pre-Submission meeting with the U.S. Food and Drug Administration (FDA) regarding its PL-1
• Polyrizon Ltd. Prices $5M Direct Offering at Premium — Dec 5, 2025 Risk: medium
  On December 5, 2025, Polyrizon Ltd. entered into a securities purchase agreement to sell 552,269 ordinary shares at $9.00 per share in a registered direct offer
• Polyrizon Reports Positive Naloxone Hydrogel Mucoadhesion Results — Dec 3, 2025 Risk: medium
  Polyrizon Ltd. announced on December 3, 2025, positive mucoadhesion results for its intranasal naloxone hydrogel. These results were compared against a currentl
• Polyrizon Ltd. Upscales Nasal Spray Manufacturing — Dec 2, 2025 Risk: low
  Polyrizon Ltd. announced on December 2, 2025, the successful completion of a key manufacturing upscaling milestone for its nasal spray platform. This achievemen
• 6-K Filing — Nov 25, 2025
• Polyrizon Ltd. Reports Viral Blocking Breakthrough — Nov 6, 2025 Risk: medium
  Polyrizon Ltd. filed a Form 6-K on November 6, 2025, to report a press release detailing their intranasal barrier-forming formulation's demonstrated reversible
• Polyrizon Ltd. Reports Positive Pre-Clinical Results for PL-14 — Oct 6, 2025 Risk: medium
  Polyrizon Ltd. announced on October 6, 2025, positive pre-clinical results for its PL-14 product. The study demonstrated encouraging allergen-blocking efficacy,
• Polyrizon Submits FDA Pre-Sub Package for Allergy Blocker — Sep 19, 2025 Risk: medium
  Polyrizon Ltd. announced on September 19, 2025, that it has submitted a pre-submission package to the U.S. Food and Drug Administration (FDA) for its PL-14 Alle
• Polyrizon Ltd. Files 6-K with Financials — Sep 17, 2025 Risk: medium
  Polyrizon Ltd. filed a Form 6-K on September 17, 2025, reporting its interim condensed financial statements as of June 30, 2025. The filing also includes Manage
• Polyrizon Ltd. Shareholders Approve All Proposals — Sep 4, 2025 Risk: low
  Polyrizon Ltd. announced on September 4, 2025, that its shareholders approved all proposals at a special general meeting. These approvals were made with the req
• Polyrizon Ltd. Regains Nasdaq Listing Compliance — Aug 14, 2025 Risk: low
  Polyrizon Ltd. announced on August 14, 2025, that it has regained compliance with Nasdaq listing requirements. This follows a period where the company may have
• Polyrizon Ltd. Calls Special Shareholder Meeting for Sept 4 — Jul 31, 2025 Risk: low
  Polyrizon Ltd. has filed a Form 6-K to announce a Special General Meeting of Shareholders scheduled for Thursday, September 4, 2025. Shareholders of record as o
• Polyrizon Ltd. Reports Successful Allergy Blocker Study — Jul 22, 2025 Risk: medium
  Polyrizon Ltd. announced on July 22, 2025, the successful intranasal delivery of its PL-14 allergy blocker in a recent study. The company is a foreign private i
• Polyrizon Ltd. Retains Nasdaq Listing — Jul 15, 2025 Risk: medium
  Polyrizon Ltd. announced on July 15, 2025, that it will retain its listing on the Nasdaq Stock Market. This decision follows hearings before the Nasdaq Hearings
• Polyrizon Ltd. Director Resigns — Jun 30, 2025 Risk: low
  Polyrizon Ltd. announced on June 25, 2025, that Omer Srugo resigned from its Board of Directors, effective immediately. The resignation was not prompted by any
• Polyrizon Reports Promising CNS Drug Delivery Results — Jun 12, 2025 Risk: medium
  Polyrizon Ltd. announced on June 12, 2025, promising results for its innovative hydrogel formulation designed for internasal delivery of CNS therapeutics. The p
• Polyrizon Ltd. Receives Nasdaq Delisting Notice — May 23, 2025 Risk: high
  Polyrizon Ltd. announced on May 23, 2025, that it received a delisting notice from Nasdaq. The company is classified under Surgical & Medical Instruments & Appa
• Polyrizon Ltd. Announces 1-for-250 Reverse Stock Split — May 22, 2025 Risk: medium
  Polyrizon Ltd. announced a 1-for-250 reverse share split of its ordinary shares, effective May 27, 2025. This consolidation will reduce the number of outstandin
• Polyrizon Ltd. Reports Positive Preclinical Data on Nasal Protection — May 21, 2025 Risk: medium
  Polyrizon Ltd. announced on May 21, 2025, positive preclinical data for its nasal protection platform. The company's press release, attached to this Form 6-K, d
• Polyrizon Ltd. Share Count Rises After Warrant Exercises — May 19, 2025 Risk: medium
  Polyrizon Ltd. announced on May 19, 2025, that the number of its issued and outstanding ordinary shares has increased. This follows additional exercises of warr
• Polyrizon Ltd.: Selling Shareholders Exercise Warrants Post-Registration — May 14, 2025 Risk: medium
  Polyrizon Ltd. announced on May 14, 2025, that selling shareholders have been exercising their warrants following the effectiveness of their Form F-1 registrati
• Polyrizon Ltd. Announces 1-for-10 Reverse Stock Split — May 1, 2025 Risk: medium
  Polyrizon Ltd. announced on May 1, 2025, that it will implement a 1-for-10 reverse share split of its ordinary shares. The company's shares will begin trading o
• Polyrizon Reports Successful Safety Study of Allergy Blocker — Apr 25, 2025 Risk: medium
  Polyrizon Ltd. announced on April 25, 2025, the successful completion of a safety study for its PL-14 Allergy Blocker formulation. The study utilized a human na
• Polyrizon Ltd. Shareholders Approve All 14 Proposals at AGM — Apr 17, 2025 Risk: low
  On April 17, 2025, Polyrizon Ltd. held its annual general meeting of shareholders. All fourteen proposals presented to the shareholders were approved, meeting t
• Polyrizon Ltd. Gets Nasdaq Minimum Bid Price Warning — Apr 11, 2025 Risk: medium
  Polyrizon Ltd. received a notification from Nasdaq on April 11, 2025, indicating that its common stock has not met the minimum bid price requirement of $1.00 pe
• Polyrizon Ltd. Hires Branding Firm for Strategic Development — Apr 2, 2025 Risk: low
  Polyrizon Ltd. announced on April 2, 2025, that it has engaged a leading branding firm to develop its strategic brand. This engagement is intended to enhance Po
• Polyrizon Ltd. Raises $17M in Private Placement — Apr 1, 2025 Risk: medium
  On March 31, 2025, Polyrizon Ltd. entered into a securities purchase agreement with institutional investors for a private placement. The company will sell appro
• Polyrizon Structures Allergy Blocker Clinical Strategy for FDA Meeting — Mar 27, 2025 Risk: medium
  Polyrizon Ltd. announced on March 27, 2025, that it is structuring its clinical strategy for its Allergy Blocker product in anticipation of an upcoming FDA pre-
• Polyrizon Ltd. Expands Epilepsy Drug Delivery Research — Mar 25, 2025 Risk: medium
  Polyrizon Ltd. announced on March 25, 2025, that it is expanding its drug delivery innovation with preclinical studies for an epilepsy rescue treatment. This ex
• Polyrizon Ltd. Eyes Psychedelic Treatments with New LOI — Mar 14, 2025 Risk: medium
  Polyrizon Ltd. announced on March 14, 2025, that it has signed a non-binding Letter of Intent (LOI) to expand its intranasal drug delivery platform, specificall
• Polyrizon Ltd. Schedules Annual Shareholder Meeting for April 17 — Mar 13, 2025 Risk: low
  Polyrizon Ltd. announced its Annual General Meeting of Shareholders will take place on Thursday, April 17, 2025, at 16:00 p.m. Israel time at the company's offi
• Polyrizon starts naloxone preclinical studies for opioid overdose — Mar 10, 2025 Risk: medium
  Polyrizon Ltd. announced on March 10, 2025, the initiation of preclinical studies for an intranasal naloxone product designed to target opioid overdose. This de
• Polyrizon Files Patent for Trap & Target™ Drug Delivery — Jan 30, 2025 Risk: low
  Polyrizon Ltd. announced on January 30, 2025, that it has filed a divisional patent application for its Trap & Target™ (T&T) intranasal drug delivery platform.
• Polyrizon Starts GMP Mfg for Allergy Blocker — Jan 23, 2025 Risk: medium
  Polyrizon Ltd. announced on January 23, 2025, that it has begun the Good Manufacturing Practice (GMP) preliminary process for its PL-14 Allergy Blocker. This ma
• Polyrizon Ltd. Appoints Liron Carmel to Board — Jan 21, 2025 Risk: low
  Polyrizon Ltd. announced on January 13, 2025, the appointment of Liron Carmel to its Board of Directors. Mr. Carmel has been the CEO of Xylo Technologies Ltd. (
• Polyrizon Ltd. Patents Hydrogel Nasal Tech — Dec 30, 2024 Risk: low
  Polyrizon Ltd. announced on December 30, 2024, the publication of a U.S. National Patent Application for its innovative hydrogel nasal technologies. This filing
• Polyrizon Ltd. Appoints Dr. Michal Meir to Lead Regulatory Affairs — Dec 19, 2024 Risk: low
  Polyrizon Ltd. announced on December 19, 2024, the appointment of Dr. Michal Meir as its new Senior Director of Regulatory and Clinical Affairs. Dr. Meir brings
• Polyrizon Ltd. Appoints New VP of Regulatory Affairs — Dec 13, 2024 Risk: low
  Polyrizon Ltd. announced on December 13, 2024, the appointment of a new Vice President of Regulatory Affairs and Quality Assurance. This appointment is detailed
• Polyrizon Secures GMP Manufacturing for PL-14 Allergy Blocker — Dec 2, 2024 Risk: medium
  Polyrizon Ltd. announced on December 2, 2024, that it has entered into a GMP manufacturing agreement with an unnamed partner for the CTM supply of its PL-14 All
• Polyrizon Ltd. Closes IPO — Oct 30, 2024 Risk: medium
  Polyrizon Ltd. announced on October 30, 2024, the successful closing of its initial public offering (IPO). The company sold 958,903 units, with each unit compri

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX